You are here: Industry Insights > Astellas

News List

Astellas has announced its acquisition of Xyphos for $665m europeanpharmaceuticalreview
January 09, 2020
Xyphos Biosciences will become a wholly owned subsidiary of Astellas Pharma following an acquisition made by the latter company.
Astellas Acquires Xyphos Biosciences americanpharmaceuticalreview
January 06, 2020
Astellas Pharma announced the company has acquired Xyphos Biosciences. With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform.
FDA approves Astellas-Seattle Genetics’ bladder cancer drug pharmaceutical-technology
December 23, 2019
The US Food and Drug Administration (FDA) has granted accelerated approval to Astellas Pharma and Seattle Genetics’ Padcev drug to treat locally advanced or metastatic urothelial cancer.
Pfizer, Astellas secure expanded FDA approval for XTANDI pharmaceutical-business-review
December 20, 2019
Pfizer and Astellas Pharma have secured approval for a new indication for XTANDI (enzalutamide) from the US Food and Drug Administration (FDA) to include its use in ...
Pfizer, Astellas' Xtandi Gets FDA nod biospectrumasia
December 18, 2019
For the treatment of patients with metastatic castration-sensitive prostate cancer
Pfizer, Astellas' Xtandi matches J&J's Erleada with new FDA nod fiercepharma
December 18, 2019
Pfizer and Astellas' stalwart prostate cancer med Xtandi has watched as Johnson & Johnson's challenger, Erleada, picked up the lead in the metastatic, castration-sensitive form of the disease.
Pfizer, Astellas' Xtandi garners expanded FDA approval to include metastatic castration-sensitive prostate cancer firstwordpharma
December 17, 2019
Pfizer and Astellas announced that the FDA expanded approval of Xtandi (enzalutamide) to include the treatment of patients with metastatic castration-sensitive prostate cancer.
Astellas enters into definitive agreement to acquire Audentes Therapeutics europeanpharmaceuticalreview
December 10, 2019
Astellas has announced that it will be acquiring Audentes Therapeutics at a total cost of $3 billion.
Seattle Genetics, Astellas gets USFDA priority review for Enfortumab Vedotin biospectrumasia
September 18, 2019
The filing is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019.
Seattle Genetics, Astellas Announce FDA Grants Review for Enfortumab Vedotin BLA americanpharmaceuticalreview
September 17, 2019
Seattle Genetics and Astellas Pharma announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin and ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page